MIRM - Mirum Pharmaceuticals Inc
IEX Last Trade
43.11
1.130 2.621%
Share volume: 331,362
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$41.98
1.13
2.69%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-09 | 2023-03-08 | 2023-05-04 | 2023-08-07 | 2023-11-02 | 2024-03-15 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 297.233 M | 364.347 M | 352.906 M | 333.530 M | 443.588 M | 650.642 M | 646.621 M | 651.962 M | |
| Current Assets | 147.245 M | 215.556 M | 190.225 M | 172.334 M | 383.518 M | 388.579 M | 387.541 M | 389.465 M | |
| Inventories | 4.524 M | 6.943 M | 5.565 M | 6.613 M | 8.509 M | 22.250 M | 22.312 M | 21.606 M | |
| Other Current Assets | 3.778 M | 6.929 M | 8.947 M | 8.987 M | 9.729 M | 12.465 M | 10.935 M | 10.017 M | |
| Short Term Investments | 3.778 M | 6.929 M | 8.947 M | 8.987 M | 9.729 M | 12.465 M | 10.935 M | 10.017 M | |
| Total Receivables | 13.990 M | 16.337 M | 23.994 M | 24.661 M | 35.326 M | 47.834 M | 67.968 M | 54.999 M | |
| Current Cash | 124.953 M | 185.347 M | 151.719 M | 132.073 M | 329.954 M | 306.030 M | 286.326 M | 302.843 M | |
| Total Non-current Assets | 149.988 M | 148.791 M | 162.681 M | 161.196 M | 60.070 M | 262.063 M | 259.080 M | 262.497 M | |
| Property Plant Equipment | 832.000 K | 795.000 K | 914.000 K | 877.000 K | 866.000 K | 787.000 K | 706.000 K | 501.000 K | |
| Other Assets | 3.084 M | 2.964 M | 2.813 M | 2.624 M | 2.767 M | 2.938 M | 5.449 M | 4.553 M | |
| Intangible Assets | 46.072 M | 45.032 M | 58.954 M | 57.695 M | 56.437 M | 258.338 M | 252.925 M | 257.443 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 297.233 M | 364.347 M | 352.906 M | 333.530 M | 443.588 M | 650.642 M | 646.621 M | 651.962 M | |
| Total liabilities | 186.546 M | 195.050 M | 210.869 M | 192.380 M | 364.978 M | 381.561 M | 397.951 M | 417.359 M | |
| Total current liabilities | 45.174 M | 51.398 M | 64.729 M | 48.843 M | 58.203 M | 74.664 M | 87.064 M | 105.909 M | |
| Accounts Payable | 8.119 M | 10.548 M | 8.690 M | 6.440 M | 14.446 M | 7.369 M | 7.416 M | 15.983 M | |
| Other liabilities | 139.855 M | 142.341 M | 144.883 M | 142.482 M | 10.000 K | 7.000 K | 3.849 M | 4.287 M | |
| Current long term debt | 752.000 K | 775.000 K | 931.000 K | 914.000 K | 1.064 M | 1.082 M | 1.104 M | 358.000 K | |
| Long term debt | 1.517 M | 1.311 M | 1.257 M | 1.055 M | 306.765 M | 306.890 M | 307.038 M | 307.163 M | |
| Other liabilities | 139.855 M | 142.341 M | 144.883 M | 142.482 M | 10.000 K | 7.000 K | 3.849 M | 4.287 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 110.687 M | 169.297 M | 142.037 M | 141.150 M | 78.610 M | 269.081 M | 248.670 M | 234.603 M | |
| Common stock | 32.164 M | 34.928 M | 36.968 M | 37.675 M | 38.107 M | 41.099 M | 46.659 M | 46.928 M | |
| Retained earnings | -320.687 M | -356.393 M | -392.824 M | -422.954 M | -496.992 M | -520.580 M | -556.239 M | -581.518 M |